Fat-loss drug Mounjaro now India's No. 2 pharma brand
Eli Lilly's weight-loss drug Mounjaro is rapidly climbing the ranks in the Indian pharmaceutical market, nearing GlaxoSmithKline's antibiotic Augmentin in monthly sales. Launched in March, Mounjaro generated Rs 80 crore in September, becoming the second-largest brand. Its high unit value contributes significantly to its impressive revenue despite lower volumes.
Eli Lilly's weight-loss drug Mounjaro is rapidly climbing the ranks in the Indian pharmaceutical market, nearing GlaxoSmithKline's antibiotic Augmentin in monthly sales. Launched in March, Mounjaro generated Rs 80 crore in September, becoming the second-largest brand. Its high unit value contributes significantly to its impressive revenue despite lower volumes.
